Key regions: Australia, Japan, United States, Germany, Europe
The Anti-Coagulants market in Central America has been experiencing notable growth in recent years.
Customer preferences: Patients in Central America are increasingly adopting anti-coagulants as a preventative measure against stroke, heart attack, and other cardiovascular diseases. This trend is driven by an aging population and a growing awareness of the benefits of early intervention and treatment.
Trends in the market: Mexico and Costa Rica are the largest markets for anti-coagulants in Central America, followed by Panama and Guatemala. The market for direct oral anticoagulants (DOACs) is growing rapidly, with patients preferring these drugs over traditional anticoagulants due to their ease of use and lower risk of bleeding. In addition, there is a growing trend towards personalized medicine, with doctors increasingly tailoring treatment plans to individual patients' needs and medical histories.
Local special circumstances: One of the key challenges in the anti-coagulants market in Central America is the lack of access to healthcare in rural areas. This has led to a concentration of demand in urban areas, particularly in larger cities such as Mexico City, San Jose, and Panama City. In addition, there is a lack of awareness among patients and healthcare providers about the risks and benefits of anti-coagulant therapy, which has resulted in suboptimal use of these drugs.
Underlying macroeconomic factors: The growth of the anti-coagulants market in Central America is being driven by several macroeconomic factors, including rising healthcare expenditure, increasing disposable incomes, and a growing burden of cardiovascular disease. In addition, the region's favorable regulatory environment and increasing adoption of electronic medical records are helping to drive growth in the market. However, challenges such as a lack of healthcare infrastructure and limited government funding for healthcare remain significant barriers to further growth in the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
